Angola vs Cape Verde: Average cost of multi drug-resistant tuberculosis treatment
Angola
537 constant 2022 US$
in 2023
Cape Verde
500 constant 2022 US$
in 2024
Angola rank
76th
Cape Verde rank
78th
Average cost of multi drug-resistant tuberculosis treatment over time
- Angola
- Cape Verde
How they compare
Angola currently reports 537 constant 2022 US$ against 500 constant 2022 US$ in Cape Verde, a difference of 37 constant 2022 US$.
That makes Angola's figure about 1.1 times Cape Verde's.
The two have swapped places 1 time across 7 shared years of data; in 2017 it was Cape Verde ahead.
Angola ranks 76th and Cape Verde ranks 78th of 92 countries.
Angola has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Angola | Cape Verde | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,284 constant 2022 US$ | 1,500 constant 2022 US$ | 784 constant 2022 US$ | Angola |
| 2020s | 1,917 constant 2022 US$ | 1,250 constant 2022 US$ | 667 constant 2022 US$ | Angola |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Angola or Cape Verde?
- Angola, at 537 constant 2022 US$ against 500 constant 2022 US$ in Cape Verde as of 2023.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Angola and Cape Verde?
- 37 constant 2022 US$, with Angola ahead.
- How many years of comparable data are there for Angola and Cape Verde?
- 7 years are reported by both, from 2017 to 2023.
- How do Angola and Cape Verde rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Angola ranks 76th and Cape Verde ranks 78th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.